EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ataxia Telangiectasia and Rad3‐Related Kinase as a Drug Target and Its Inhibitors: Synthetic Aspects, Current Research and Potential Perspectives

Pranav Bhagwat iD, Sivapriya Kirubakaran iD

Archiv der Pharmazie · 2026-11 · 359 (11)

DOI: 10.1002/ardp.70379 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 02.11.2026. Verfasst von Pranav Bhagwat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Ataxia Telangiectasia Mutated Proteins, Ataxia Telangiectasia. Die Arbeit nennt 185 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ATR kinase is a key regulator of the DNA damage response and replication stress, with two decades of homology model‐based drug design now validated by cryo‐EM structures of full‐length human ATR‐ATRIP. This review treats ATR drug discovery as both a synthetic chemistry and structural challenge, outlining reagent‐level pathways from initial hits to drug substances for clinical candidates. It includes multi‐kilogram biocatalytic and photoredox‐flow routes for ceralasertib, analysing the strategic logic behind each scheme, a focus absent in recent SAR‐based reviews. We analyse the binding modes observed in the recent ~3 Å ATR–ATRIP inhibitor co‐structures and compare them with previous PI3K homology model predictions. Additionally, we expand the discussion on selectivity to include not only the ( R )‐3‐methylmorpholine pocket but also the aminopyrazine and macrocyclic chemotypes. The section on PROTACs is reoriented around degrading the ATR‐CHK1‐ATM pathway, highlighting a CHK1 degrader and ATM degrader that synergise with ATR inhibition. Finally, ATR's roles beyond oncology are considered, including neurodevelopment, mitochondrial homoeostasis, gametogenesis, and in parasitic DDR. Overall, in the current scenario, ATR inhibitors are positioned as promising candidates for repurposing in biomarker‐guided therapies, balancing potency, selectivity, toxicity and resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAtaxia Telangiectasia Mutated ProteinsAtaxia TelangiectasiaHumansAnimalsDrug DesignProteolysis Targeting ChimeraStructure-Activity RelationshipDrug DiscoveryMolecular Structure

Stichwörter der Autor:innen

ATR inhibitorsAtaxia telangiectasia and Rad3‐related kinaseCryo‐EMPROTAC degradersProcess chemistrySynthetic lethality

Substanzen

Protein Kinase InhibitorsAtaxia Telangiectasia Mutated ProteinsATR protein, humanProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Chemistry, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, India.

ORCID-Profile: Pranav Bhagwat, Sivapriya Kirubakaran

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Bhagwat, P., & Kirubakaran, S. (2026). Ataxia Telangiectasia and Rad3‐Related Kinase as a Drug Target and Its Inhibitors: Synthetic Aspects, Current Research and Potential Perspectives. Archiv der Pharmazie, 359(11). https://doi.org/10.1002/ardp.70379

Vancouver

Bhagwat P, Kirubakaran S. Ataxia Telangiectasia and Rad3‐Related Kinase as a Drug Target and Its Inhibitors: Synthetic Aspects, Current Research and Potential Perspectives. Archiv der Pharmazie. 2026;359(11). doi:10.1002/ardp.70379

BibTeX
@article{Bhagwat2026,
  author = {Bhagwat, Pranav and Kirubakaran, Sivapriya},
  title = {Ataxia Telangiectasia and Rad3‐Related Kinase as a Drug Target and Its Inhibitors: Synthetic Aspects, Current Research and Potential Perspectives},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {11},
  doi = {10.1002/ardp.70379}
}
Kostenlos starten →